LONG-TERM RESULTS OF INTRAVITREAL RANIBIZUMAB, INTRAVITREAL RANIBIZUMAB WITH PHOTODYNAMIC THERAPY, AND INTRAVITREAL TRIAMCINOLONE WITH PHOTODYNAMIC THERAPY FOR THE TREATMENT OF RETINAL ANGIOMATOUS PROLIFERATION
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
In Brief Purpose: To compare intravitreal ranibizumab, intravitreal ranibizumab plus photodynamic therapy (PDT), and intravitreal triamcinolone plus PDT in retinal angiomatous proliferation, presenting the results of a 3-year follow-up. Methods: Thirty-seven eyes of 37 patients with retinal angiomatous proliferation were randomized to 1 of the 3 groups. Group 1 (n = 13) received 3 monthly injections of 0.5 mg ranibizumab, Group 2 (n = 13) received 1 session of PDT and 3 monthly injections of ranibizumab, and Group 3 (n = 11) received 1 session of PDT and 1 injection of 4 mg triamcinolone. Retreatment, with the same therapeutic scheme in each group, was considered in case of persistence or recurrence of subretinal/intraretinal fluid. Results: Twelve patients in Groups 1 and 2 and 9 patients in Group 3 completed the 3-year follow-up. A total of 58% of patients in Group 1, 50% in Group 2, and 88.9% in Group 3 had the same or better visual acuity at the end of the follow-up (P = 0.081). Patients in Group 3 exhibited considerable improvement in visual acuity (P = 0.032) and statistically significant decrease in central retinal thickness (P < 0.0001) than the 2 other groups at the end of the follow-up. Also, the patients in Group 3 received on average the lowest number of injections (P < 0.0001). Of note, geographic atrophy mainly at the place of previous retinal angiomatous proliferation lesion was detected in 0% in Group 1, 25% in Group 2, and 55.6% in Group 3 (P = 0.203), while 33.3% of patients in Group 1 developed retinal scar. Conclusion: Treatment with ranibizumab or ranibizumab plus PDT resulted in stabilization of the disease, while treatment with IVT plus PDT achieved better results in terms of functional and anatomical features compared with the other groups. Our study compares three therapeutic modalities against retinal angiomatous proliferation. Treatment with ranibizumab or ranibizumab plus photodynamic therapy resulted in stabilization of the disease, while treatment with intravitreal triamcinolone plus photodynamic therapy achieved better results in terms of functional and anatomical features compared with the other groups.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“but a more recent study reported that only one third of the RAP lesions treated with three 0.5-mg intravitreal injections of ranibizumab and followed up for 3 years developed retinal scarring.39”
From Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials (2014) · cites this paper as [39]
Citations
Cites
(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
RETINAL ANGIOMATOUS PROLIFERATION IN AGE–RELATED MACULAR DEGENERATION
Yannuzzi, L. A., Negrão, S., IIDA, T., Carvalho, C., Rodriguez-Coleman, H., Slakter, J., Freund, K. B., Sorenson, J., Orlock, D., & Borodoker, N. (2012) · Retina · doi:10.1097/iae.0b013e31823f9b3b · Cited by 660 · cited 6×
“Retinal angiomatous proliferation accounts for 10% to 15% of all neovascular age-related macular degeneration in white patients and 4.5% in Japanese patients,2,3 but its natural course is believed to be worse 1181 than that of typical exudative age-related macular degeneration; therefore, its recognition is essential.…”
BackgroundInfluentialRETINAL ANGIOMATOUS PROLIFERATION IN AGE-RELATED MACULAR DEGENERATION
YANNUZZI, L. A., NEGRÃO, S., IIDA, T., CARVALHO, C., RODRIGUEZ-COLEMAN, H., SLAKTER, J., FREUND, K. B., SORENSON, J., ORLOCK, D., & BORODOKER, N. (2001) · Retina · doi:10.1097/00006982-200110000-00003 · Cited by 659
Clinical Characteristics of Exudative Age-related Macular Degeneration in Japanese Patients
Maruko, I., Iida, T., Saito, M., Nagayama, D., & Saito, K. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.03.047 · Cited by 544
Bottoni, F. (2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.12.1644 · Cited by 129
Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration
Cohen, S. Y., Creuzot-Garcher, C. P., Darmon, J., Desmettre, T. J., Korobelnik, J., Levrat, F., Quentel, G., Palies, S., Sanchez, A., de Gendre, A. S., et al. (2007) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.115501 · Cited by 124
Photodynamic therapy for retinal angiomatous proliferations and pigment epithelium detachment
Boscia, F., Furino, C., Sborgia, L., Reibaldi, M., & Sborgia, C. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2004.06.072 · Cited by 92
INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR RETINAL ANGIOMATOUS PROLIFERATION
MEYERLE, C. B., FREUND, K. B., ITURRALDE, D., SPAIDE, R. F., SORENSON, J. A., SLAKTER, J. S., KLANCNIK, J. M., FISHER, Y. L., COONEY, M. J., & YANNUZZI, L. A. (2007) · Retina · doi:10.1097/iae.0b013e318030ea80 · Cited by 88 · cited 6×
“Retinal angiomatous proliferation accounts for 10% to 15% of all neovascular age-related macular degeneration in white patients and 4.5% in Japanese patients,2,3 but its natural course is believed to be worse 1181 than that of typical exudative age-related macular degeneration; therefore, its recognition is essential.…”
BackgroundInfluentialGEOGRAPHIC ATROPHY IN RETINAL ANGIOMATOUS PROLIFERATION
Mcbain, V. A., Kumari, R., Townend, J., & Lois, N. (2011) · Retina · doi:10.1097/iae.0b013e3181fe54c7 · Cited by 85
RETINAL ANGIOMATOUS PROLIFERATION: Natural History and Progression of Visual Loss
VIOLA, F., MASSACESI, A., ORZALESI, N., RATIGLIA, R., & STAURENGHI, G. (2009) · Retina · doi:10.1097/iae.0b013e3181a395cb · Cited by 79 · cited 1×
“” There is a controversy about which is the most appropriate treatment of RAP, although it is generally considered that RAP has a poor prognosis because it typically progresses to severe stages ending in a disciform scar.(12) Before the introduction of anti–vascular endothelial growth factor (anti-VEGF) agents, there…”
Background
Cited by
Sun, X., Yang, S., & Zhao, J. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s97653 · Cited by 347
Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials
Daniel, E., Toth, C. A., Grunwald, J. E., Jaffe, G. J., Martin, D. F., Fine, S. L., Huang, J., Ying, G.-S., Hagstrom, S. A., Winter, K., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.10.019 · Cited by 335
“5-mg intravitreal injections of ranibizumab and followed up for 3 years developed retinal scarring.(39) Although further investigation is warranted, these data suggest that anti-VEGF treatment prevents scar formation from RAP lesions.”
Local delivery of corticosteroids in clinical ophthalmology: A review
Fung, A. T.-C., Tran, T., Lim, L. L., Samarawickrama, C., Arnold, J., Gillies, M. C., Catt, C. J., Mitchell, L., Symons, R. C. A., Buttery, R., et al. (2019) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.13702 · Cited by 129
Daniel, E., Shaffer, J., Ying, G., Grunwald, J. E., Martín, D., Jaffe, G. J., & Maguire, M. G. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.10.034 · Cited by 110
Retinal angiomatous proliferation
Tsai, A. S. H., Cheung, N., Gan, A. T. L., Jaffe, G. J., Sivaprasad, S., Wong, T. Y., & Cheung, C. M. G. (2017) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2017.01.008 · Cited by 82
“In a study with the longest follow up to-date (3 years), Rouvas et al compared the treatment effect of ranibizumab alone to PDT and ranibizumab to PDT and IVTA.(97) In this study that included all RAP stages, surprisingly, visual acuity improvement was only seen in the group treated with PDT and”
Broadhead, G., Hong, T., & Chang, A. (2014) · Acta Ophthalmologica · doi:10.1111/aos.12463 · Cited by 61
“Retinal angiomatous proliferation has previously been reported to have poor visual gain in response to anti-VEGF monotherapy (Hemeida et al. 2010; Rouvas et al. 2012).”
BackgroundGharbiya, M., Parisi, F., Cruciani, F., Pantaleoni, F. B., Pranno, F., & Abdolrahimzadeh, S. (2013) · Retina · doi:10.1097/iae.0b013e3182979e62 · Cited by 40
Cho, H. J., Lee, T. G., Han, S. Y., Kim, H. S., Kim, J. H., Han, J. I., Lew, Y. J., & Kim, J. W. (2015) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-015-2993-3 · Cited by 38
Shin, J. Y., & Yu, H. G. (2014) · Retina · doi:10.1097/iae.0000000000000225 · Cited by 37
Clinical Pathological Features and Current Animal Models of Type 3 Macular Neovascularization
Qiang, W., Wei, R., Chen, Y., & Chen, D. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.734860 · Cited by 26
“However, more patients who received IVTA developed GA and underwent cataract surgery (Rouvas et al., 2012).”
BackgroundKim, J. H., Kim, J. W., Kim, C. G., & Lee, D. W. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041145 · Cited by 21
Kim, Y., Park, S. J., Woo, S. J., & Park, K. H. (2016) · Retina · doi:10.1097/iae.0000000000000952 · Cited by 19
Park, Y. G., & Roh, Y. (2015) · BMC Ophthalmology · doi:10.1186/s12886-015-0172-2 · Cited by 17
“Rouvas et al [23, 24] reported that patients treated with ranibizumab monotherapy, intravitreal triamcinolone plus PDT, or ranibizumab plus PDT resulted in stabilization of the disease.”
BackgroundCLINICOPATHOLOGIC CORRELATION OF RETINAL ANGIOMATOUS PROLIFERATION TREATED WITH RANIBIZUMAB
Skalet, A. H., Miller, A. K., Klein, M. L., Lauer, A. K., & Wilson, D. J. (2017) · Retina · doi:10.1097/iae.0000000000001672 · Cited by 16
Seidel, G., Werner, C., Weger, M., Steinbrugger, I., & Haas, A. (2013) · Acta Ophthalmologica · doi:10.1111/aos.12111 · Cited by 13
Browning, A. C., O’Brien, J. M., Vieira, R., Gupta, R., & Nenova, K. (2019) · Ophthalmologica · doi:10.1159/000500203 · Cited by 13
Fallico, M., Macchi, I., Maugeri, A., Favara, G., Barchitta, M., Lio, R. M. S., Agodi, A., Russo, A., Longo, A., Avitabile, T., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1141077 · Cited by 10
“, 2020) provided data on 12-month follow-up, while 4 studies (Rouvas et al., 2012; Gharbiya et al., 2014; MaruyamaInoue et al., 2019; Kim, 2020) did not report 12-month outcomes, providing only outcomes at 24 months or longer.”
BackgroundMethodInfluentialShort-term efficacy of intravitreal Aflibercept injections for retinal angiomatous proliferation
Chou, H., Wu, W., Wang, N., Chuang, L., Chen, K., & Lai, C. (2017) · BMC Ophthalmology · doi:10.1186/s12886-017-0497-0 · Cited by 10
Treatment Effects in Retinal Angiomatous Proliferation Imaged with OCT Angiography
de Jong, J. H., Braaf, B., Amarakoon, S., Gräfe, M. G. O., Yzer, S., Vermeer, K. A., Missotten, T., de Boer, J. F., & van Velthoven, M. E. J. (2018) · Ophthalmologica · doi:10.1159/000491798 · Cited by 9
Giacomelli, G., Giansanti, F., Finocchio, L., Biagini, I., Bacherini, D., Virgili, G., & Menchini, U. (2013) · Retina · doi:10.1097/iae.0000000000000007 · Cited by 7
Kim, J. M., Kim, J. H., Chang, Y. S., Kim, J. W., Kim, C. G., & Lee, D. W. (2017) · Korean Journal of Ophthalmology · doi:10.3341/kjo.2016.0026 · Cited by 7
Malamos, P., Tservakis, I., Kanakis, M. G., Koutsiouki, C., Kiskira, E., Mylonas, G., Lakoumentas, J., & Georgalas, I. (2018) · Ophthalmologica · doi:10.1159/000487610 · Cited by 6
Vitreous in Age-Related Macular Degeneration
Krebs, I., & Glittenberg, C. G. (2014) · Cited by 5
III.G. Vitreous in Age-Related Macular Degeneration
Krebs, I., Glittenberg, C. G., & Binder, S. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1086-1_19 · Cited by 3
Marques, M. F., Marques, J. P., Gil, J., Costa, J. C., Almeida, E., Cachulo, M. L., Pires, I., Figueira, J., & da Silva, R. M. (2015) · Ophthalmic Research · doi:10.1159/000441797 · Cited by 3
Kim, J. H. (2016) · Journal of Retina · doi:10.21561/jor.2016.1.1.11 · Cited by 2
“[36]은 상기 2009년 Retina 잡지에 발표한 연구 [28]의 36개월 장기 임상 결과를 2012년 Retina 잡지에 보고하 는데, 라니비주맙 단일요법 군과 광역학치료 + 라니비주맙 군 의 경우 36개월 시력은 진단 당시와 비교하여 유의한 호전이 없었으나 광역학치료 + 유리체강내 트리암시놀론 주입술 군의 경우 유의한 시력 호전이 나타났다.”
InfluentialKim, J. H. (2017) · Journal of Retina · doi:10.21561/jor.2017.2.2.109 · Cited by 1
Šarenac, T., Žgavc, M. G., & Mekjavič, P. J. (2016) · Slovenian Medical Journal · doi:10.6016/zdravvestn.1534
Kikushima, W., Sakurada, Y., Tsuru, D. V., & Kashiwagi, K. (2025) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-025-01189-0
Li, Y., Fu, X., Ling, H., Xiao, L., & Chen, D. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1811978
Metadata
- Authors
- Rouvas, A. A., Chatziralli, I. P., Theodossiadis, P. G., Moschos, M. M., Kotsolis, A. I., & Ladas, I. D.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Corresponding author
- Rouvas, Alexandros A.
- Theodossiadis, Panagiotis G.
- Venue
- Retina
- Published
- 2012-06
- Volume
- 32
- Issue
- 6
- Pages
- 1181-1189
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2074013967
- Cited by
- 30
- References
- 45
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 1 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 2 · 2017: 5 · 2016: 4 · 2015: 4 · 2014: 4 · 2013: 4
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Retina (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- ranibizumab, photodynamic therapy, intravitreal triamcinolone acetonide, retinal angiomatous proliferation, geographic atrophy, retinal scarring, visual acuity, central retinal thickness, anti-VEGF therapy, long-term outcomes, subretinal fluid, intraretinal fluid, retreatment, anti-inflammatory therapy, anti-angiogenic therapy, choroidal neovascularization
- MeSH terms
- Ranibizumab, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Photochemotherapy, Triamcinolone, Visual Acuity, Retinal Neovascularization, Angiogenesis Inhibitors, Intravitreal Injections, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.